Navigation Links
aRNA in Medical News

Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments

... SAN DIEGO, Aug. 3, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today reported financial results for the second quarter ended June 30, 2009. Arena reported a lower net loss allocable to common stockholder...

Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

... SAN DIEGO, July 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at...

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009

... SAN DIEGO, July 29, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afte...

Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock

... SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of th...

Arena Pharmaceuticals Announces Public Offering of Common Stock

... SAN DIEGO, July 7, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. will be the sole underwriter for t...

American Orthopaedic Society for Sports Medicine (AOSSM) Presents Prestigious Research Awards at Annual Meeting

...rican Journal of Sports Medicine will be presented to Britt Elin Øiestad, PT, MS, Lars Engebretsen, MD, PhD, Kjersti Storheim, PT, PhD, and May arna Risberg, PT, PhD for their paper "Knee osteoarthritis after anterior cruciate ligament injury - A systematic review." In this paper, the aut...

Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference

... SAN DIEGO, June 18, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the Piper Jaffray Fourth Annual Europe Conference on June 23, 2009 at 9:30 a.m. Britis...

Arena Pharmaceuticals to Receive $100 Million from Deerfield Management

... SAN DIEGO, June 17, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that it has entered into an agreement with Deerfield Management, a leading healthcare investment organization and significant Aren...

Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference

... SAN DIEGO, May 13, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the 34th Annual Deutsche Bank Health Care Conference on May 19, 2009 at 10:10 a.m. Eas...

Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints

... Conference Call Scheduled for Today at 8:30 a.m. EDT SAN DIEGO, March 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today positive top-line results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of tw...

More>>

aRNA in Medical Technology

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

...d on Previously Announced Positive Top-Line Results - NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesit...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

... - Late-Breaking Abstract Accepted - SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity M...

Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results

... SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced it will hold a conference call and webcast on Monday, March 30, 2009 at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss t...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

... SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical t...

Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

... SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The init...

Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis

... SAN DIEGO, July 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced positive results from a multiple-ascending dose Phase 1b clinical trial of APD791 to evaluate the compound's safety, pharmacokinetic...

Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies

...intenance - - Phase 2b Subjective Study Ongoing - SAN DIEGO, June 12 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that Dr. Thomas Roth of Henry Ford Hospital presented data from Arena's positive Phase 2a clinical trial of APD125 for the treatment...

Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.

... SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that Taisho Pharmaceutical Co., Ltd. initiated a Phase 1 clinical trial of a drug candidate under a GPCR-focused partnership with Ar...

Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

... SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candida...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical trial ...
aRNA in Biological Technology

High Throughput aRNA Amplification

MessageAmp II-96 aRNA Amplification Kit Amplify as little as 100 ng of input RNA in a single round for GeneChip analysis Includes ArrayScript, an engineered M-MLV RT, to maximize yields of full-length cDNA ...

Synthesize High Yields of Biotinylated aRNA

MessageAmp II-Biotin Enhanced: A Single Round aRNA Amplification Kit Ambion now offers an improved MessageAmp II Kit with biotin-11-UTP. MessageAmp II-Biotin Enhanced provides a complete single round amplification kit for bioti...

Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference

... SAN DIEGO, June 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the 8th Annual Needham Life Sciences Conference on June 11, 2009 at 11:00 a.m. Eastern...

Arena Pharmaceuticals Announces First Quarter 2009 Financial Results

... SAN DIEGO, May 11, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today reported financial results for the first quarter ended March 31, 2009. Arena reported a net loss allocable to common stockholders in the...

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009

... SAN DIEGO, May 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afterno...

Beacon Equity Issues Trade Alerts on Market Movers: CAH, LEAP, FISV, PBG, ARNA, LEN

...s International Inc. (Nasdaq: LEAP ), Fiserv Inc. (Nasdaq: FISV ), Pepsi Bottling Group Inc. (NYSE: PBG ), Arena Pharmaceuticals Inc. (Nasdaq: arna ) and Lennar Corp. (NYSE: LEN ). Join the fastest growing investment community at: http://www.stockhideout.com See what Crame...

Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million

... SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today it has obtained an equity financing commitment of up to $50 million from Azimuth Opportunity Ltd. During the 18-month term of the eq...

Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference

... SAN DIEGO, Jan . 8 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the 27th Annual J.P. Morgan Healthcare Conference on January 14, 2009 at 3:00 p.m. Pacif...

Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference

... SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) announced today that the company is scheduled to present at the Oppenheimer 19th Annual Healthcare Conference on November 4, 2008 at 8:40 a.m. Easte...

Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008

... SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: arna ) today announced it will report third quarter 2008 financial results after the NASDAQ Global Market closes on Thursday, October 30, 2008. That same a...
aRNA in Biological Products

5X MEGAscript® T7 Kit from Ambion

Description:... Exclusive ultra high yield technology is fast - 2 hour reaction time Amplifies arna for gene array analysis Efficiently incorporates many modified nucleotides Kits specific for templates with T7, T3 and SP6 RNA polymerase prom...
Company:Ambion
Other Tags
(Date:3/5/2015)... (PRWEB) March 05, 2015 University ... university founded in 1904, has launched a new ... positive lifestyle changes. The Northwest Center for Lifestyle ... professionals, support community outreach, and conduct research in ... medicine, diet and nutrition. The center will target ...
(Date:3/5/2015)... Dr. Jonathan Glashow a board certified New ... named by Castle Connolly as a Top ... has been selected by Castle Connolly Medical Ltd. for ... care doctors in the tri-state metropolitan New York area ... carefully screens and selects doctors through a rigorous peer ...
(Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... that it is now running on 100% pollution-free ... provider, Arcadia Power. , As an Arcadia ... Environmental Protection Agency’s (EPA) Green Power Partnership requirements, ... and Starbucks that also purchase clean energy. Earth ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
(Date:3/5/2015)... 05, 2015 Altec Products, Inc., a ... today their participation in the Houston, TX and Charlotte, ... Inspire Tour will unite Sage enterprise resource planning (ERP) ... workable solutions to real-world business challenges. , The ... Plaza Houston Galleria Area on March 10th. The Charlotte, ...
Breaking Medicine News(10 mins):Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 2Health News:Altec Attends Sage Inspire Tour Stops in Houston and Charlotte to Showcase Sage ERP Document Management and Workflow Solution 3
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, N.C. , Feb. 5, 2015 ... as a specialist logistics company and has launched a ... industry,s only Clinical Logistics Organization (CLO).  The new campaign ... with emphasis on patient, protocol and shipments. ... Patient First , aligns Marken,s priorities with its ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2
Other Contents